Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells and averts lupus nephritis

This study demonstrates that knocking down the long isoform of the prolactin receptor (LFPRLR) using a splice-modulating oligomer selectively targets pathogenic immune cells, reduces type I interferon signaling and autoreactive antibodies, and prevents lupus nephritis in SLE-prone mice without harming healthy immune cells, offering a promising new therapeutic strategy for systemic lupus erythematosus.

The Gist

The Big Picture: A Case of "Wrong Instructions" in the Immune System

Imagine your immune system is a highly trained security team for your body. Its job is to spot and destroy invaders like viruses and bacteria. In Systemic Lupus Erythematosus (SLE), this security team gets confused. Instead of just attacking invaders, they start attacking your own body—your skin, joints, and especially your kidneys. This is an autoimmune disease.

For a long time, doctors knew that a hormone called Prolactin (usually known for helping mothers produce milk) was often high in Lupus patients and seemed to make the disease worse. But they didn't know why or how to stop it without hurting the patient.

This paper discovers that the problem isn't just that there is too much Prolactin; it's that the cells have the wrong version of the receiver for the hormone.

The Analogy: The Radio and the Static

Think of the Prolactin Receptor (PRLR) on a cell as a radio antenna.

• The Short Antenna (Short Isoform): This is the "normal" setting. When it receives a signal, it tells the cell to calm down, differentiate, or stop dividing. It's like a "stop" or "chill" button.
• The Long Antenna (Long Isoform): This is the "amplified" setting. When it receives a signal, it tells the cell to grow, survive, and multiply aggressively. It's like a "go, go, go!" button.

In healthy people: The immune cells have a good mix of both antennas, or mostly the "Short" ones. The system stays balanced.

In Lupus patients: Something goes wrong with the cell's "instruction manual" (splicing). The cells start building way too many Long Antennas and not enough Short ones.

• The Result: The immune cells are constantly hearing the "Go, Go, Go!" signal. They multiply out of control, become aggressive, and start attacking the body. They also produce "bad" antibodies (like a security guard shooting at the neighbors instead of the burglars).

The Breakthrough: A "Tuning Fork" for Cells

The researchers didn't just want to block the hormone (which would be like jamming the radio signal for everyone, including healthy cells). Instead, they invented a Splice-Modulating Oligomer (SMO).

Think of this SMO as a smart tuning fork or a software patch.

• It goes into the cell and fixes the "instruction manual."
• It stops the cell from building the dangerous Long Antenna.
• Crucially, it allows the cell to keep building the safe Short Antenna.

What Happened When They Tried It?

The team tested this "tuning fork" in two ways:

1. In the Lab (Human Samples):
They took blood from Lupus patients and healthy donors and treated the cells with the SMO.

• In Healthy Cells: Nothing bad happened. The cells stayed healthy. The "tuning fork" didn't break anything.
• In Lupus Cells: The magic happened. The aggressive, angry cells calmed down. They stopped multiplying as fast, and they stopped acting like they were at war. The "bad" immune cells (like the ones that cause kidney damage) shrank back to normal levels.

2. In Mice (Living Models):
They gave the SMO to mice that naturally develop Lupus.

• The Kidneys: Lupus is famous for destroying kidneys (Lupus Nephritis). In the treated mice, the kidneys stayed healthy. The "glomeruli" (the tiny filters in the kidney) didn't get clogged or swollen.
• The Blood: The mice had fewer of the "bad" antibodies and fewer of the aggressive immune cells.
• The Safety: The mice didn't get sick from the treatment itself. It didn't wipe out their good immune system.

Why Is This a Big Deal?

Current Lupus treatments are like using a sledgehammer.

• Steroids and other drugs suppress the entire immune system. This stops the attack, but it also leaves the patient vulnerable to infections and cancer. It's like firing the whole security team to stop one bad guard.

This new approach is like retraining the specific bad guards.

• It targets only the cells with the "Long Antenna" problem.
• It leaves the healthy cells alone.
• It fixes the root cause (the wrong instructions) rather than just masking the symptoms.

The Bottom Line

This paper suggests that Lupus is driven by a specific glitch where immune cells build the wrong type of receptor for a hormone. By using a tiny molecule to fix that glitch, scientists can potentially turn off the "attack mode" of the disease without turning off the body's ability to fight real infections.

It's a shift from "shutting down the whole system" to "fixing the specific software bug" that causes the chaos. This could lead to a future where Lupus patients live normal lives without the heavy side effects of current drugs.

Technical Summary

1. Problem Statement

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by multi-organ inflammation, driven largely by autoreactive B cells and autoantibodies. While elevated circulating levels of the hormone prolactin (PRL) correlate with SLE exacerbation, the mechanistic link between PRL and disease pathogenesis remains unclear.

• Limitations of Current Therapies: Existing treatments (steroids, pan-B-cell depletion, plasma cell depletion) lack specificity, failing to eradicate multiple pathogenic immune subsets simultaneously while causing significant toxicity to healthy cells.
• The Knowledge Gap: It is unknown how PRL drives autoreactivity. Specifically, the role of alternative splicing of the Prolactin Receptor (PRLR) in SLE immune cells has not been characterized. PRLR exists in long (LF), intermediate (IF), and short (SF) isoforms; LF promotes proliferation/survival, while SF promotes differentiation/apoptosis.

2. Methodology

The study employed a multi-modal approach combining human clinical samples, in vitro models, and in vivo mouse models to establish causality and therapeutic potential.

• Human Samples:
  • Cohorts: Peripheral Blood Mononuclear Cells (PBMCs) from 20 SLE patients and 10 healthy donors (bulk RNA-seq); 34 SLE patients and 12 healthy donors (single-cell RNA-seq, scRNA-seq).
  • Ex Vivo Treatment: PBMCs were treated with a Splice-Modulating Oligomer (SMO) designed to knock down the Long Form PRLR (LFPRLR) by blocking exon 10 inclusion.
  • Analysis: High-dimensional flow cytometry, qPCR, and scRNA-seq were used to assess immunophenotypes, gene expression (specifically Type I Interferon genes), and cell viability.
• Mouse Models:
  • Model: 6-week-old female MRL-lpr mice (SLE-prone) treated for 8 weeks with LFPRLR SMO via subcutaneous Alzet minipumps (100 pmol/hour/mouse).
  • Controls: Healthy C57BL/6J mice and MRL-lpr mice treated with control SMO.
  • Analysis: scRNA-seq of splenic leukocytes, immunoglobulin sequencing (VDJ analysis) to assess CDR3 length and isotype, and histological analysis of kidney glomeruli (H&E staining) to measure cellularity and pathology.
• Molecular Tools:
  • SMO: A morpholino DNA oligonucleotide conjugated to an octaguanidine dendrimer to ensure cell uptake, specifically targeting the splicing of PRLR exon 10.
  • Sequencing: Bulk RNA-seq, scRNA-seq (10x Genomics), and VDJ sequencing for antibody repertoire analysis.

3. Key Contributions

• Discovery of Aberrant Splicing: The authors identified that SLE immune cells exhibit aberrant splicing of PRLR, resulting in a significantly increased ratio of the Long Form (LFPRLR) to Short Forms (SFPRLR). This skewing is driven by reduced alternative splicing efficiency specifically in PRLR+ cells.
• Causal Link Establishment: By using a specific SMO to knock down LFPRLR, the study demonstrated that the altered isoform ratio is causal to the pathogenic immune phenotypes in SLE, not merely a biomarker.
• Selective Targeting: The study proved that LFPRLR knockdown selectively targets pathogenic subsets in SLE patients without affecting healthy donor cells, addressing a major limitation of current broad immunosuppressants.
• Therapeutic Efficacy: The research provides the first evidence that correcting PRLR splicing can avert glomerular kidney damage (lupus nephritis) in a preclinical model.

4. Key Results

A. Human Ex Vivo Findings

• Isoform Shift: SLE patients showed elevated total PRLR expression, specifically the LFPRLR isoform. Monocytes and NK cells showed the highest PRLR expression.
• Pathogenic Phenotype Reversal: LFPRLR knockdown in SLE PBMCs (but not healthy PBMCs) resulted in:
  • Monocytes: A shift from immature CD14+CD16- (classical) to mature CD14+CD16+ (intermediate/non-classical) subsets.
  • NK Cells: Reduction of immature, inflammatory CD56brightCD16- cells and restoration of mature CD56dimCD16+ cytotoxic cells.
  • B Cells: Reduced expression of activation marker CD69 on IgD+ B cells and reduced proliferation of pathogenic subsets.
  • Other Subsets: Reduction in plasmacytoid dendritic cells (pDCs), atypical B cells (CD137+CXCR3+), and proliferating cytotoxic T cells.
• Interferon Suppression: Knockdown significantly reduced the expression of Type I Interferon Stimulated Genes (ISGs) such as MX1, MX2, IRF7, STAT1, and STAT2, which are known biomarkers for SLE disease activity.
• Safety: No negative impact on cell viability or the phenotype of healthy donor immune cells was observed.

B. In Vivo Mouse Findings

• Immune Homeostasis: LFPRLR knockdown in MRL-lpr mice reduced the proportion of PRLR+ splenic leukocytes and normalized the transcriptional signatures of Germinal Center (GC) and transitional B cells to resemble healthy mice.
• Plasma Cell Reduction: There was a significant reduction in both PRLR+ and PRLR- plasma cells, driven by decreased proliferation (Ki67+) rather than increased apoptosis.
• Antibody Repertoire: The treatment reduced the frequency of antibodies with long CDR3 regions (>15 amino acids), a hallmark of autoreactivity. It also increased the proportion of non-class-switched antibodies, suggesting a reduction in pathogenic, high-affinity autoantibody production.
• Kidney Protection: Most critically, LFPRLR knockdown averted glomerular pathology. Treated mice showed:
  • Normalized glomerular tuft size and cellularity (preventing hypercellularity).
  • No significant proteinuria (outlier analysis showed 0/3 treated mice had proteinuria vs. 3/3 control mice).

5. Significance and Implications

• Novel Mechanism: The study elucidates that local autocrine/paracrine PRL signaling through the LFPRLR isoform drives SLE pathogenesis, independent of pituitary PRL levels. This explains why dopamine agonists (which lower pituitary PRL) have limited efficacy, as they do not affect extrapituitary PRL.
• Precision Medicine: Unlike CAR-T cell therapies or broad B-cell depleters, LFPRLR SMO acts as a "molecular switch" that normalizes the immune system by correcting a specific splicing defect. It spares healthy immune function, potentially avoiding the severe immunosuppression and infection risks associated with current SLE treatments.
• Clinical Potential: The LFPRLR SMO represents a promising therapeutic candidate that could treat both the autoimmune and the lymphoma risks associated with SLE (as LFPRLR also drives B-cell lymphomagenesis).
• Kidney Protection: The ability to prevent glomerular hypercellularity suggests this approach could halt the progression of lupus nephritis, a major cause of morbidity and mortality in SLE patients.

In conclusion, this paper establishes the long isoform of the prolactin receptor as a master regulator of SLE pathogenicity and proposes a splice-modulating oligomer as a highly specific, effective, and safe therapeutic strategy to restore immune homeostasis and prevent organ damage.